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Synopsis 
S-nitrosothiol compounds are important mediators of NO signalling and can give rise to 
various redox derivatives of NO: Nitrosonium cation (NO+), nitroxyl anion (NO-) and 
NO· radical. Several enzymes and transporters have been implicated in the intracellular 
delivery of NO from S-nitrosothiols. In this study we have investigated the role of 
glutathione peroxidase (GPx), the L-amino acid transporter (L-AT) system and protein 
disulphide isomerase (PDI) in the delivery of NO redox derivatives into human 
platelets. 
 
Washed human platelets were treated with inhibitors of GPx, L-AT and PDI prior to 
exposure to donors of NO redox derivatives (S-nitrosoglutathione, Angeli’s salt and 
Diethylamine NONOate). Rapid delivery of NO-related signalling into platelets was 
monitored by cGMP accumulation and DAF-FM fluorescence. 
 
All NO redox donors produced both a cGMP response and DAF-FM fluorescence in 
target platelets. NO delivery was blocked by inhibition of PDI in a dose-dependent 
manner. In contrast, inhibition of GPx and L-AT had only a minimal effect on NO-
related signalling. 
 
PDI activity is therefore required for the rapid delivery into platelets of NO-related 
signals from donors of all NO redox derivatives. GPx and the L-AT system appeared to 
be unimportant in rapid NO signalling by the compounds used in this study. This does 
not, however, exclude a possible role during exposure of cells to other S-nitrosothiol 
compounds, such as S-nitrosocysteine. These results further highlight the importance of 
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S-nitrosothiol compounds (RSNOs), produced by S-nitrosation of cysteine thiols,  
feature prominently in the biology of nitric oxide (NO) as mediators of both signalling 
events and nitrosative stress [1]. The easy synthesis, relative stability and NO-related 
biological activity of RSNOs make them potentially useful therapeutic tools with a wide 
range of clinical applications [2], in particular as platelet-selective anti-thrombotic 
agents [3]. Nevertheless, the NO-related signalling actions of RSNOs are independent 
of their rate of NO release [4, 5] and the mechanism by which they deliver NO into cells 
is debated. There exists what has been described as a “gulf between our chemical 
understanding of S-nitrosothiols and the proposed biological activities of these 
compounds” [6]. However, a picture is emerging of RSNO action being mediated at the 
target cell surface via stereoselective recognition sites [7], L-Amino acid Transporters 
(L-ATs) [8, 9] and metabolising enzymes [10-12].  
 
Several reports have highlighted the possibility that NO delivery may involve an 
extracellular transnitrosation step in which the RSNO acts as a nitrosonium (NO+) 
donor, transferring this either to a cell surface thiol-bearing protein such as protein 
disulphide isomerase (PDI) [13] or to a low molecular weight thiol such as cysteine, 
prior to trans-membrane transport of S-nitrosocysteine (CSNO) via the L-AT system 
[9]. A further interesting observation is that extracellular glutathione peroxidase (GPx) 
potentiates platelet inhibition by RSNOs, possibly by facilitating transnitrosation 
reactions [14].  
 
It may be that RSNO action involves a variety of modes of cellular metabolism and 
transmembrane NO delivery, tailored to provide both signalling specificity and also, 
under conditions of RSNO excess, cellular defence against nitrosative stress. A further 
layer of complexity arises from the diverse chemistry of RSNO compounds, which 
under physiological conditions can give rise to various redox derivatives of NO. Thus 
metal-catalysed RSNO decomposition produces NO radical (NO˙), transnitrosation 
involves transfer of nitrosonium cation (NO+) and S-thiolation reactions release nitroxyl 
anion (NO-) [15]. There has been recent interest in the fact that these various redox 
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derivatives, in particular nitroxyl, show distinct biological properties [16], including a 
differential ability to stimulate generation of the classic second messenger cGMP. In 
fact, some reports have suggested that NO radical is the only redox form to stimulate 
soluble guanylate cyclase [17].  
 
In this study we have investigated the role of GPx, L-AT and PDI in the delivery of NO 
signalling into human platelets from the RSNO compound S-nitrosoglutathione 
(GSNO). In addition, we have used well-characterised donors of both NO radical and 
nitroxyl anion to determine whether L-AT, GPx and PDI mediate intra-platelet delivery 





In order to establish which, if any, of the candidate enzyme/transporter systems may be 
involved in the delivery of nitric oxide across the platelet membrane, recognised 
pharmacological inhibitors of GPx, the L-AT system and PDI were used and NO entry 
into platelets was measured after addition of NO donors. Three different donors of NO 
redox derivatives were used: GSNO (an NO+ donor), Angeli’s salt (an NO- donor), and 
Diethylamine NONOate sodium salt (DEANO) (a donor of free nitric oxide, NO·). 
 
Materials and reagents  
Angeli’s salt was purchased from Merck Biosciences Ltd (Nottingham, UK), 4-amino-
5-methylamino-2’7-difluorofluorescein (DAF-FM) diacetate from Molecular Probes 
(Eugene, OR), and RL90 antibody against PDI from Alexis Biochemicals (Nottingham, 
UK). Reagents for cGMP measurement by enzyme immunoassay were obtained from 
Amersham Biosciences (Chalfont St. Giles, UK). All other chemicals were purchased 
from Sigma (Poole, UK).  
 
Preparation of washed platelets 
Washed platelets were prepared from informed healthy volunteers who had not received 
any medication known to alter platelet function for at least 2 weeks before the study. 
Blood was anticoagulated with acid citrate dextrose (ACD) and processed within 1 hour 
of collection. Platelet rich plasma (PRP) was obtained by centrifuging the blood twice at 
170g for 10 minutes, keeping the upper layer each time. PRP was acidified with 0.5 M 
citric acid to pH 6.3 and prostaglandin E1 (PGE1) (1.5 µM) and apyrase (2 U/ml) were 
added prior to centrifugation at 1000g for 12 minutes. The platelet pellet obtained was 
then resuspended in 1.5 ml HEPES buffered saline (HBS), containing NaCl (140 mM), 
KCl (2.7 mM), Glucose (5 mM), BSA (1 mg ml-1) and HEPES (10 mM) (pH 7.3) and 
loaded onto a Sepharose 2B column (5-6 ml packed Sepharose in a 1.5 cm column 
equilibrated with HBS). The platelet fraction was eluted with HBS and platelet count 
adjusted to 200×109 l-1. Finally, CaCl2 and MgCl2 were added to a final concentration of 
1 mM. 
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Preparation of S-nitrosoglutathione (GSNO) 
GSNO was prepared as previously described [5] by nitrosation under acid conditions. 
Briefly, equal volumes of glutathione (20 mM) and sodium nitrite (20 mM) were 
incubated in the presence of 100 mM HCl on ice for 30 minutes. GSNO was stabilised 
by addition of 1 mM EDTA. GSNO was freshly prepared each day and stored in the 
dark on ice until used. The concentration of GSNO was estimated by its absorbance at 
334 nm using an extinction coefficient of 0.85 mM-1 cm-1. 
 
Preparation of Angeli’s salt and DEANO 
20 mM stock solutions of Angeli’s salt and DEANO were prepared in 10 mM NaOH 
and diluted immediately prior to use in HBS. 
 
Cyclic GMP accumulation in response to NO donor 
NO donors were incubated with platelets at 37ºC for 2 minutes, after which an equal 
volume of 20% v/v perchloric acid was added and samples stored at -20ºC. Immediately 
prior to assay, pH was corrected to 7.4 by addition of K3PO4 (0.54 M), after which 
samples were centrifuged to remove precipitate and cGMP measured by enzyme 
immunoassay.  
 
Measurement of entry of reactive nitrogen species (NOx) using DAF-FM 
fluorescence 
DAF-FM diacetate is a membrane permeant fluorescent probe used for detecting 
intracellular NO. Platelets suspended in HBS without BSA were treated with DAF-FM 
diacetate (1 µM) for 30 minutes at 37°C and then loaded onto a Sepharose 2B column. 
The DAF-FM-loaded platelets were clearly separated from free DAF-FM and were 
collected and adjusted to 200×109 l-1, in HBS containing 1 mM CaCl2 and MgCl2 as 
before. Fluorescence intensity (FI) at 515 nm with excitation at 495 nm was measured 
using a FLUOstar OPTIMA plate reader (BMG Labtechnologies) as an indicator of the 




Investigation of the role of GPx in NO delivery 
Platelet-rich plasma was pre-incubated with 10-1000 µM β-mercaptosuccinic acid or 
0.1-10 mM zinc chloride for 30 minutes at 37°C to inhibit GPx, prior to the addition of 
NO donor. cGMP levels were then measured as described above.  
 
In separate experiments, washed platelet suspensions were supplemented with GPx 
(Sigma, UK) to final concentrations of 0.1-20 U ml-1, prior to measurement of cGMP 
responses. A glutathione peroxidase cellular activity assay kit from Sigma (Poole, UK) 
was used to measure GPx in platelet poor plasma. Concentrations of 0.0075 U ml-1 were 
found and this plasma GPx activity was completely inhibited by β-mercaptosuccinic 
acid and zinc chloride at concentrations of 1000 µM and 10 mM, respectively (data not 
shown).  
 
Investigation of the role of L-AT in NO delivery 
L-leucine, as a typical substrate of the L-AT system, and BCH, as a selective inhibitor 
of L-AT, were used at concentrations of 1-10 mM to competitively block the activity of 
this transport mechanism. Both have previously been shown to inhibit the entry of 
CSNO into human epithelial cells in this concentration range [8]. BCH, L-leucine and, 
as a control, D-leucine, were pre-incubated with washed platelets for 30 minutes at 
37°C prior to the addition of NO donor when measuring cGMP levels, and with DAF-
FM-loaded washed platelets when measuring fluorescence as an indicator of NO entry.  
 
Investigation of the role of PDI in NO delivery 
The ability of bacitracin, phenylarsine oxide (PAO) and the anti-PDI antibody, RL90 to 
inhibit the disulphide exchange activity of 0.16 µM PDI (Sigma) was monitored using 
an insulin turbidity assay, as previously described [18].  cGMP levels and DAF-FM 
fluorescence were measured after pre-incubation of washed platelets for 30 minutes at 




10 µM GSNO, 10 µM Angeli’s salt and 1 µM DEANO were all found to promote a 
similar cGMP response in washed platelets and these concentrations were therefore 
used in subsequent studies (figure 1a). When cGMP was measured in PRP, 10-fold 
higher concentrations of each donor were required. 
 
For studies using DAF-FM fluorescence to monitor delivery of NOx into platelets, 10 
µM Angeli’s salt and 1 µM DEANO were found to give similar increases in 
fluorescence intensity (FI) and these concentrations were therefore used in experiments 
with DAF-FM-loaded platelets. Smaller increases in FI were obtained with GSNO, 




Effect of inhibition of GPx on cGMP generation 
cGMP generation stimulated by GSNO, Angeli’s salt and DEANO in PRP was 
inhibited to a minor degree (maximum 30%) by both β-mercaptosuccinic acid and zinc 
chloride (figure 2), however this inhibition failed to show a clear dose response 
relationship. 
 
Effect of GPx supplementation on GSNO-stimulated cGMP generation in washed 
platelets 
Addition of GPx had the effect of increasing GSNO-stimulated cGMP production in 
platelets, however levels of GPx required to show this effect were approximately 1000 
times higher than the concentration of GPx found in plasma (0.0075 U ml-1). GPx 
supplementation had no effect on Angeli’s salt- or DEANO-stimulated cGMP 






L-Amino Acid Transporter System 
Neither BCH (1-10 mM), nor L-leucine (1-10 mM) significantly inhibited cGMP 
generation stimulated by any of the NO donors (figures 4a and b). D-leucine was also 
shown to have no effect (data not shown). 
 
In parallel experiments, NOx entry measured fluorometrically in DAF-FM-loaded 
platelets was unaffected by either BCH or L-leucine (data not shown). 
 
PDI 
Inhibition of PDI by bacitracin, PAO and RL90 
All three agents produced concentration-dependent inhibition of PDI activity however 
the degree of inhibition was smaller with RL90 than with bacitracin or PAO (figure 5).  
 
Platelet cGMP responses are inhibited by bacitracin 
NO donors were added to washed platelets in the presence of bacitracin (0-5 mM), 
RL90 (0-20 µg ml-1) and PAO (0-100 µM). cGMP accumulation resulting from 
stimulation by all NO donors was inhibited in a dose-dependent manner by bacitracin 
(figure 6). The effect of RL90 and PAO, however, was less clear. RL90 had a minimal 
effect on cGMP accumulation in response to GSNO and DEANO, although it had some 
effect with Angeli’s salt. Conversely, PAO, at concentrations of 10 and 100 µM 
completely inhibited cGMP accumulation with all NO donors (data not shown).  
 
Experiments using YC-1 suggest direct interference of RL90 and PAO with soluble 
guanylate cyclase   
To investigate the inconsistent effects of the different PDI inhibitors on cGMP 
responses we investigated whether the inhibitors might exert a direct effect on the 
action of soluble guanylate cyclase, using the NO-independent activator YC-1 [19]. PDI 
inhibitors were pre-incubated with washed platelets after which 100 µM YC-1 was 
added. cGMP responses were unchanged with bacitracin (5 mM), increased 
approximately three-fold with RL90 (20 µg ml-1), and almost completely abolished with 
PAO (100 µM) (data not shown). Since RL90 and PAO interfered directly with soluble 
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NO entry into DAF-FM-loaded platelets is inhibited by bacitracin, RL90 and PAO 
Experiments using DAF-FM-loaded platelets indicated that PDI plays a role in delivery 
of all redox derivatives of NO. Pre-incubation of DAF-FM-loaded platelets with 
bacitracin, RL90 and PAO produced a dose-dependent inhibition of FI in response to all 
three NO donor compounds (figure 7). Control experiments performed in the absence of 
NO donors showed that the PDI inhibitors themselves produced no change in DAF-FM 





The principal finding of this study is that PDI activity is required for the delivery into 
platelets of NO-related signals from donors of all NO redox derivatives. Under the 
experimental conditions used, GPx and the L-AT system appeared to be unimportant in 
NOx delivery.  
 
Two systems, cGMP accumulation and DAF-FM fluorescence, were used to detect the 
arrival of NOx inside the target platelets and a positive response was obtained with both 
detection systems following treatment of platelets with donors of all three NO redox 
derivatives.  Previous reports have suggested that only NO˙ is capable of activating 
soluble guanylate cyclase [17], however this result was obtained using the purified 
enzyme and there are numerous data showing that in whole platelets a cGMP response 
is obtained in response to GSNO [20, 21], DEANO [5] and Angeli’s salt [22]. This 
indicates either that the responsiveness of soluble guanylate cyclase is in fact wider than 
previously believed, or that nitroxyl is at least partly converted to NO˙ once inside the 
cell [23]. Diamino fluorophores, including DAF-FM, are widely used as intracellular 
indicators of NO˙ production, however is it now recognised that fluorescence marks 
reaction of the probe with NOx rather than the NO˙ radical itself [24, 25]. Thus in the 
current study a positive signal is interpreted simply as evidence of NOx entry, and the 
exact identity of the delivered reactive nitrogen species remains uncertain. 
 
We were interested to investigate the role of GPx in platelet regulation by NO because 
of its possible clinical significance. In the late 1990s a novel thrombotic tendency was 
reported, first in a single family [26] and later in a larger study of seven families [27], in 
which deficiency of plasma GPx was associated with both platelet resistance to GSNO 
and an increased incidence of childhood stroke. An earlier paper had suggested that 
plasma GPx could potentiate the anti-platelet action of GSNO via two mechanisms: a) 
reduction of lipid peroxides thereby preventing them from inactivating NO, and b) an 
ability of extracellular GPx to catalyse transnitrosation [14].  Certain observations 
reported in these studies suggested to us that the second mechanism was more likely. 
For example, sodium nitroprusside-induced inhibition of platelet aggregation was not 
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altered by GPx [14], suggesting its effects might be an RSNO-related phenomenon, and 
not more generally relevant to other NO donor compounds. Also, intraplatelet GPx (as 
opposed to extracellular GPx in the plasma) was found to be normal when measured in 
one affected family [26], suggesting that the GPx effect was exerted outside the platelet, 
for example via catalysis of transnitrosation from an RSNO to a target on the exofacial 
surface of the plasma membrane. Despite these considerations, we did not find evidence 
in the current study that plasma GPx mediates the transfer of NO-related signalling into 
platelets. β-mercaptosuccinate and zinc chloride, at concentrations shown to completely 
inhibit plasma GPx, showed only a limited ability to inhibit cGMP generation following 
addition of NO donors, and this minor inhibition was not dose-dependent. It should be 
noted that previous authors monitored platelet aggregation and P-selectin surface 
expression, whereas we focussed on cGMP accumulation as a marker of intracellular 
NO delivery. This technical difference may in part explain our different findings. 
Consistent with Freedman et al. [14],  we found that addition of GPx to washed 
platelets increased cGMP accumulation in response to GSNO (though not to DEANO or 
Angeli’s salt), however, the amounts of GPx required were almost 1000-fold higher 
than the levels we found in plasma. Given this, it appears unlikely that the effect has 
physiological relevance. 
 
There is ample evidence that CSNO is transported across the plasma membrane in a 
stereoselective manner via the L-AT system. This has been demonstrated in  a variety of 
cell types including PC 12 neuronal cells [28], RAW 264.7 macrophages [9] and the 
carcinoma cell lines A431 and T24 [8]. We found, however, no inhibition of 
intraplatelet NOx delivery from GSNO, DEANO or Angeli’s salt, in the presence of the 
well characterised inhibitors BCH and L-leucine, at concentrations shown in previous 
studies to block CSNO uptake on the L-amino acid transporter system [8]. GSNO is not 
a direct substrate for this transporter, and for L-AT to mediate NO delivery from GSNO 
extracellular cysteine must be available (either directly or via reduction of cystine) so 
that CSNO can be produced via transnitrosation, prior to transport [9, 29]. Neither 
cysteine nor cystine was supplied in our experiments and this may explain why we 
found no evidence for the involvement of L-AT. The fact remains, however, that all 
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three NO donors were capable of rapidly and effectively bringing about both cGMP 
accumulation and DAF-FM fluorescence in platelets, and so some other entry 
mechanism must exist.  
 
The current study produced clear evidence that inhibitors of PDI prevent the 
intracellular delivery of NO-related signals (cGMP accumulation and DAF-FM 
fluorescence) from GSNO in a dose dependent manner. These results are consistent 
with those of Zai et al. [30] and Ramachandran et al. [13] who also found that PDI 
inhibition  produced inhibition of NO delivery from RSNOs (measured as cGMP 
accumulation and quenching of N-dansylhomocysteine fluorescence, respectively). PDI 
has been shown to denitrosate GSNO [18] and it is postulated that the NO˙ released by 
this reaction combines with oxygen in the hydrophobic environment of either the cell 
membrane or the PDI protein itself to form N2O3 [31], which then passes on the NO 
signal via nitrosation of intracellular thiols, completing the transmembrane delivery 
process [13]. We were surprised, however, also to find evidence of PDI involvement in 
the intracellular delivery of NOx from both DEANO and Angeli’s salt. We had 
anticipated that free NO˙ released by DEANO would be able to diffuse into platelets 
unaided, by virtue of its lipophilicity. If the role of platelet membrane PDI in RSNO 
action is to denitrosate prior to transmembrane transfer of NOx, then it is not clear why 
such a mechanism should be required following platelet exposure to DEANO. The 
ingress of nitroxyl-derived species from Angeli’s salt is reported to involve reaction 
with oxygen to form a long-lived diffusible intermediate which penetrates the cell via 
partitioning into the cell membrane [32]. Our own results showed that the degree of 
inhibition of intracellular NOx entry caused by bacitracin, PAO and RL90 varied 
between different donor compounds (GSNO, DEANO and Angeli’s salt) and detection 
systems (cGMP accumulation and DAF-FM fluorescence), and did not always correlate 
closely with the degree of inhibition of authentic PDI  caused by these agents, 
suggesting a variable degree of PDI dependence for the delivery of different NO redox 
derivatives. Although the detailed chemistry is not yet clear, our data suggest overall 
that PDI facilitates the transfer across the platelet membrane of both NO˙-derived and 
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nitroxyl-derived species, possibly through the intermediate formation of “NO-charged 
PDI” [31]. 
 
Recent research has revealed a significant role for both PDI [33] and other thiol 
isomerases [34, 35] in platelet responses. Nitric oxide is an important physiological 
regulator of platelet function and our data further highlight the importance of PDI in 
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Figure 1  
Measurement of cGMP accumulation and DAF-FM fluorescence intensity 
following exposure of washed platelets to NO redox derivatives 
Intracellular delivery of reactive nitrogen species (NOx) from donors of NO redox 
derivatives: GSNO, Angeli’s salt (AS) and DEANO, was measured by (a) cGMP 
accumulation and (b) change in DAF-FM fluorescence intensity (∆ FI). 
 
Figure 2 
Inhibition of cGMP accumulation by inhibitors of glutathione peroxidase, in 
response to donors of different NO redox derivatives 
GSNO, Angeli’s salt (AS) and DEANO were added to platelets, resulting in an 
accumulation cGMP. Inhibition of this accumulation by inhibitors of GPx: (a) β-
mercaptosuccinate and (b) zinc chloride was monitored. Results represent mean of 6-8 
experiments. Error bars are omitted for clarity. 
 
Figure 3 
cGMP accumulation in response to donors of different NO redox derivatives, 
following addition of GPx to washed platelet suspensions 
Glutathione peroxidase was added to washed platelets. cGMP accumulation was then 
measured following exposure of the platelets to GSNO, Angeli’s salt and DEANO. 
Results represent mean and s.e.mean from 4 experiments. 
 
Figure 4 
Inhibition of cGMP accumulation by inhibitors of L-AT, in response to donors of 
different NO redox derivatives 
The effect of L-AT inhibitors: (a) BCH and (b) L-Leucine, on cGMP accumulation in 
response to donors of different NO redox derivatives was monitored. Results represent 





Inhibition of PDI enzyme activity by bacitracin, PAO and RL90 
Disulphide exchange activity of authentic PDI (0.16 µM) was measured by insulin 
turbidity assay in the presence of bacitracin (0.05, 0.5 and 5 mM), PAO (1, 10 and 100 
µM) and RL90 anti-PDI antibody (0.2, 2 and 20 µg ml-1) and the degree of enzyme 
inhibition calculated by comparison with activity obtained using vehicle control. Values 
shown represent mean and s.e.mean from 3-4 experiments. 
 
Figure 6 
Inhibition of cGMP accumulation by an inhibitor of PDI, in response to donors of 
different NO redox derivatives 
The PDI inhibitor, bacitracin, was pre-incubated with washed platelets. Inhibition of 
cGMP accumulation in response to donors of different NO redox derivatives: GSNO, 
Angeli’s salt (AS) and DEANO, was measured. Results represent mean and s.e.mean 
from 6-8 experiments. 
 
Figure 7 
Increases in DAF-FM fluorescence in response to donors of different NO redox 
derivatives are inhibited by inhibitors of PDI  
GSNO, Angeli’s salt and DEANO were added to DAF-FM-loaded platelets, resulting in 
increases in DAF-FM fluorescence over a period of 10 minutes. Increasing 
concentrations of (a) bacitracin, (b) RL90 and (c) PAO pre-incubated with these 
platelets resulted in a dose-related inhibition of this increase in fluorescence intensity. 
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